Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, T-Cell, Peripheral 3Recurrence 2Neoplasm Metastasis 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Smoking 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × 10-propargyl-10-deazaaminopterin × Clear all
NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

Phase 2 Completed
30 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡